Free Trial

Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare logo
$128.69 -0.20 (-0.16%)
(As of 02:33 PM ET)

Addus HomeCare - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
1
Hold
0
Buy
10

Based on 11 Wall Street analysts who have issued ratings for Addus HomeCare in the last 12 months, the stock has a consensus rating of "Buy." Out of the 11 analysts, 1 has given a sell rating, 8 have given a buy rating, and 2 have given a strong buy rating for ADUS.

Consensus Price Target

$133.67
3.87% Upside
According to the 11 analysts' twelve-month price targets for Addus HomeCare, the average price target is $133.67. The highest price target for ADUS is $150.00, while the lowest price target for ADUS is $83.00. The average price target represents a forecasted upside of 3.87% from the current price of $128.69.
Get the Latest News and Ratings for ADUS and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Addus HomeCare and its competitors.

Sign Up

ADUS Analyst Ratings Over Time

TypeCurrent Forecast
12/27/23 to 12/26/24
1 Month Ago
11/27/23 to 11/26/24
3 Months Ago
9/28/23 to 9/27/24
1 Year Ago
12/27/22 to 12/27/23
Strong Buy
2 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
7 Buy rating(s)
7 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$133.67$131.63$128.29$107.00
Forecasted Upside3.87% Upside5.80% Upside-2.03% Downside12.02% Upside
Consensus Rating
Buy
Moderate Buy
Moderate Buy
Buy

ADUS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ADUS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Addus HomeCare Stock vs. The Competition

TypeAddus HomeCareMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.81
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside3.87% Upside25,889.15% Upside13.36% Upside
News Sentiment Rating
Positive News

See Recent ADUS News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
12/16/2024Citizens Jmp
0 of 5 stars
C. Davides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
12/16/2024JMP Securities
2 of 5 stars
 Initiated CoverageOutperform$150.00+20.00%
11/14/2024Royal Bank of Canada
4 of 5 stars
 Reiterated RatingOutperform ➝ Outperform$136.00 ➝ $136.00+10.90%
11/6/2024Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$143.00 ➝ $145.00+11.66%
11/4/2024Macquarie
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$139.00 ➝ $139.00+9.41%
10/11/2024KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$150.00+17.70%
9/23/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$140.00 ➝ $145.00+10.30%
8/8/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$128.00 ➝ $137.00+10.88%
5/7/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$115.00 ➝ $118.00+20.54%
4/23/2024Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeEqual Weight ➝ Underweight$83.00-11.22%
2/5/2024William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform
8/2/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$100.00 ➝ $105.00+12.98%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:49 PM ET.


ADUS Forecast - Frequently Asked Questions

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Addus HomeCare is $133.67, with a high forecast of $150.00 and a low forecast of $83.00.

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last twelve months. There is currently 1 sell rating, 8 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADUS shares.

According to analysts, Addus HomeCare's stock has a predicted upside of 3.87% based on their 12-month stock forecasts.

Over the previous 90 days, Addus HomeCare's stock had 2 upgrades by analysts.

Addus HomeCare has been rated by research analysts at Citizens Jmp, JMP Securities, KeyCorp, Macquarie, Royal Bank of Canada, and Stephens in the past 90 days.

Analysts like Addus HomeCare more than other "medical" companies. The consensus rating for Addus HomeCare is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ADUS compares to other companies.


This page (NASDAQ:ADUS) was last updated on 12/26/2024 by MarketBeat.com Staff
From Our Partners